Accelerating Therapeutic DiscoveryTM

Application Instructions

If you are interested in receiving support for a research project that falls into one of the categories listed on our Therapeutic Strategies, please follow the application instructions.

Click to download: Letter of Interest and Full Application Instructions

Thank you for your interest in ending the effects of COPD and liver disease caused by Alpha-1 Antitrypsin Deficiency.

Select the search type
  • Site
  • Web
Search

About The Alpha-1 Project

The Alpha-1 Project (TAP) is a wholly owned subsidiary of the Alpha-1 Foundation singularly focused on bridging the gap between clinical trials and commercialization of therapies for the elimination of Chronic Obstructive Pulmonary Disease (COPD) and liver disease caused by Alpha-1 Antitrypsin Deficiency (Alpha-1).

Learn More

Latest News

Apic Bio Announces $40M Series A Financing to Advance Novel Gene Therapies for Rare Genetic Disorders
Scientific founders who originated the miRNA mediated “silence and replace” approach take on Alpha-1 and ALS US ...
Posted on January 07, 2019
Adverum Biotechnology Provides Program Updates
Based on the most recent data from the ADVANCE clinical trial, the Company is reviewing the learnings from the study, notably...
Posted on December 17, 2018

General Contact

The Alpha-1 Project

3300 Ponce de Leon Boulevard
Coral Gables, FL 33134
Phone: 305-648-9541
Toll-free: 888-920-0002
Fax: 305-441-2110
Email: info@thealpha-1project.com

The Alpha-1 Project Alpha-1 Antitrypsin Deficiency Therapeutic Strategies Clinical Trial Resources Progress Reports About Us Login
Copyright (c) 2019 The Alpha 1 Project All Rights Reserved | Terms Of Use | Privacy Statement
The Alpha-1 Project® is a registered trademark of the Alpha-1 Foundation, Inc.
Accelerating Therapeutic Discovery™ is a registered trademark of The Alpha-1 Foundation, Inc.
Website by IMI Software, Inc.